MANTLE CELL LYMPHOMA TREATMENT IN
CHINA — BTK INHIBITORS AND CAR-T

Most patients with mantle cell lymphoma do not start by searching for a country. They start with a clinical reality. The disease has relapsed earlier than expected, the BTK inhibitor has stopped working, the local oncologist has mentioned CAR-T but cannot offer it, or the family has been told the lymphoma carries a TP53 mutation and behaves aggressively. At this stage, families need a structured next step rather than a list of options. China has built one of the largest cell therapy and lymphoma trial ecosystems in the world. Several CD19 CAR-T products are approved for relapsed B-cell lymphoma, and many academic and specialist centres run trials specifically relevant to mantle cell lymphoma, including dual-target CAR-T (CD19/CD20 or CD19/CD22), allogeneic CAR-T, CAR-NK, and combinations of BTK inhibitors with venetoclax or anti-CD20 antibodies. Domestic Chinese BTK inhibitors such as zanubrutinib and orelabrutinib are widely used, often at meaningfully lower cost than originator drugs in the United States or Europe. China is most relevant for mantle cell lymphoma when the disease has relapsed after a BTK inhibitor, when TP53 mutation makes standard chemoimmunotherapy less reliable, when CAR-T is being considered before transplant, or when newer combinations and trial-stage agents are needed.

Mantle cell lymphoma is a mature B-cell lymphoma defined by the t(11;14) translocation, which leads to overexpression of cyclin D1. Most cases are confirmed by a combination of histology, immunohistochemistry showing CD20, CD5, and cyclin D1 positivity, and molecular or FISH testing for t(11;14). SOX11 expression is also typical. Mantle cell lymphoma covers a wide clinical spectrum. Some patients have indolent leukaemic non-nodal disease that can be observed for years. Most have classical nodal disease that requires treatment, often with widespread involvement at diagnosis. A subset has blastoid or pleomorphic morphology, which behaves more aggressively. The Ki-67 proliferation index is an important prognostic marker — higher values suggest more aggressive behaviour. TP53 mutation is the single most important biological factor that changes treatment thinking. TP53-mutated mantle cell lymphoma responds poorly to standard chemoimmunotherapy and stem cell transplant, and most experts now move to BTK inhibitor-based or CAR-T-based pathways earlier in these patients. The MIPI score also helps with risk classification, but TP53 status, Ki-67, and morphology often drive the most important treatment decisions.

First-Line Treatment Treatment is shaped by age, fitness, and biology. Younger and fit patients have traditionally received intensive cytarabine-containing regimens such as Nordic protocols or R-CHOP alternating with R-DHAP, often followed by autologous stem cell transplant and rituximab maintenance. Older or less fit patients are usually treated with bendamustine-rituximab, R-CHOP, or VR-CAP, also followed by rituximab maintenance. More recently, BTK inhibitor-based chemo-light or chemo-free regimens are increasingly used in first line, especially in TP53-mutated disease and in patients unsuited to intensive chemotherapy. Combinations of BTK inhibitors with rituximab and venetoclax, or with bendamustine-rituximab, are active areas of clinical use and trial work in China and globally. A small group of patients with truly indolent leukaemic non-nodal mantle cell lymphoma may be safely observed initially, although this requires careful confirmation of the indolent variant. BTK Inhibitors BTK inhibitors block Bruton tyrosine kinase, a key signal in B-cell receptor pathway activation, which is essential for mantle cell lymphoma cell survival. They are central to relapsed and refractory disease, and increasingly used in first-line settings. Several BTK inhibitors are available in China, including zanubrutinib (a domestically developed second-generation BTK inhibitor with broad approvals), ibrutinib, acalabrutinib, and orelabrutinib, another domestic agent. Newer covalent and non-covalent BTK inhibitors, including pirtobrutinib-class agents for patients who have progressed on covalent BTK inhibitors, are accessible through clinical trials in selected centres. BTK inhibitor monotherapy or combination regimens are usually given as long-term oral therapy. Side effects can include atrial fibrillation, bleeding tendency, hypertension, and infections, with differences between agents that influence drug choice. CAR-T Cell Therapy CAR-T therapy uses the patient's own T cells, genetically modified to recognise the CD19 antigen on B-lymphoma cells. After leukapheresis, manufacturing, lymphodepleting chemotherapy, and infusion, the engineered cells expand and attack residual lymphoma. Brexucabtagene autoleucel was the first CAR-T product specifically approved for relapsed or refractory mantle cell lymphoma globally, including after BTK inhibitor failure. In China, CD19 CAR-T products are approved for relapsed B-cell lymphomas, and several Chinese-developed CAR-T platforms are in active clinical trial use for mantle cell lymphoma. Trial-stage cellular therapies include dual-target constructs (CD19/CD20, CD19/CD22), allogeneic off-the-shelf CAR-T, and CAR-NK approaches. CAR-T is now established as an important option after BTK inhibitor failure and in patients unsuitable for, or relapsing after, autologous stem cell transplant. Other Targeted and Combination Options Beyond BTK inhibitors and CAR-T, additional options include venetoclax (BCL2 inhibitor), lenalidomide-based combinations, bortezomib-containing regimens, and bispecific antibodies engaging T cells against CD20. Allogeneic stem cell transplant remains a consideration in selected younger patients with chemo-sensitive relapse, particularly in centres with strong transplant programmes. Sequencing of these therapies depends on prior treatments, response, fitness, and local availability.

Eligibility is always reviewed by the treating hospital and depends on multiple factors:

• Confirmed pathology of mantle cell lymphoma with cyclin D1 e

  Confirmed pathology of mantle cell lymphoma with cyclin D1 expression and t(11;14) by FISH or molecular testing

• CD19 or CD20 expression confirmed by IHC or flow cytometry,

  CD19 or CD20 expression confirmed by IHC or flow cytometry, depending on the planned product

• Relapsed or refractory disease, especially after BTK inhibit

  Relapsed or refractory disease, especially after BTK inhibitor exposure and chemoimmunotherapy

• TP53 mutation status, Ki-67 index, and blastoid or pleomorph

  TP53 mutation status, Ki-67 index, and blastoid or pleomorphic morphology, which often justify earlier use of CAR-T and trial therapies

• No clinically significant CNS lymphoma, or treated and stabl

  No clinically significant CNS lymphoma, or treated and stable CNS disease in selected protocols

• Adequate organ function — heart, liver, kidney, lung — with

  Adequate organ function — heart, liver, kidney, lung — with attention to cardiac risk in patients on or after BTK inhibitors

• Acceptable blood counts and bone marrow reserve for lymphode

  Acceptable blood counts and bone marrow reserve for lymphodepletion and post-CAR-T cytopenia management

• ECOG performance status, typically 0 to 2, depending on prot

  ECOG performance status, typically 0 to 2, depending on protocol

• No active uncontrolled infection, including hepatitis B, hep

  No active uncontrolled infection, including hepatitis B, hepatitis C, or HIV; treated and stable infections may still allow access depending on the protocol

• Sufficient T-cell counts for CAR-T manufacturing and ability

  Sufficient T-cell counts for CAR-T manufacturing and ability to tolerate lymphodepleting chemotherapy

• Travel fitness and a realistic plan for several weeks of in-

  Travel fitness and a realistic plan for several weeks of in-country care, including bridging therapy if required during the manufacturing window

The completeness of records often determines how quickly a meaningful plan can be built. The following are typically requested:

• Latest medical summary and treating haematologist's opinion

  Latest medical summary and treating haematologist's opinion

• Original biopsy and histopathology report confirming mantle

  Original biopsy and histopathology report confirming mantle cell lymphoma, including morphology (classical, blastoid, pleomorphic) and Ki-67 index

• IHC report including CD20, CD19, CD5, cyclin D1, SOX11, and

  IHC report including CD20, CD19, CD5, cyclin D1, SOX11, and Ki-67

• FISH or molecular report for t(11;14) and TP53 status

  FISH or molecular report for t(11;14) and TP53 status

• Bone marrow aspiration and biopsy report

  Bone marrow aspiration and biopsy report

• Flow cytometry report from blood or bone marrow

  Flow cytometry report from blood or bone marrow

• Recent PET CT report covering neck to thigh, and any prior P

  Recent PET CT report covering neck to thigh, and any prior PET CT for comparison

• CT, MRI, or endoscopy reports as relevant, including gastroi

  CT, MRI, or endoscopy reports as relevant, including gastrointestinal evaluation if symptomatic

• Complete blood count, LDH, beta-2 microglobulin, liver and k

  Complete blood count, LDH, beta-2 microglobulin, liver and kidney function tests

• Hepatitis B, hepatitis C, HIV, and other viral screening res

  Hepatitis B, hepatitis C, HIV, and other viral screening results

• ECG and echocardiogram, particularly relevant given BTK inhi

  ECG and echocardiogram, particularly relevant given BTK inhibitor cardiac considerations

• Detailed treatment history with regimens, cycles, dates, res

  Detailed treatment history with regimens, cycles, dates, response, and reasons for stopping, including all BTK inhibitor exposure and reasons for discontinuation

CancerFax supports mantle cell lymphoma cases through a structured pathway:

• Case review — diagnosis, morphology, Ki-67, TP53 status, pri

  Case review — diagnosis, morphology, Ki-67, TP53 status, prior BTK inhibitor exposure, and current disease behaviour are reviewed against the most relevant treatment options.

• Pathology and biomarker check — IHC, FISH, flow cytometry, a

  Pathology and biomarker check — IHC, FISH, flow cytometry, and molecular reports are checked, and missing investigations such as TP53 testing or repeat biopsy are flagged before hospital review.

• Hospital and trial matching — the case is shared with approp

  Hospital and trial matching — the case is shared with appropriate Chinese cancer centres running approved CAR-T programmes, BTK-inhibitor combination protocols, or clinical trials in mantle cell lymphoma.

• Bridging strategy — for patients with progressing disease du

  Bridging strategy — for patients with progressing disease during the CAR-T manufacturing window, CancerFax helps coordinate timing between current local treatment and admission in China.

• Cost and stay planning — patients receive a clear picture of

  Cost and stay planning — patients receive a clear picture of expected hospital charges, lymphodepletion, infusion, monitoring, accommodation, and follow-up timelines.

• Travel and admission support — visa guidance, interpreter co

  Travel and admission support — visa guidance, interpreter coordination, hospital communication, and admission planning are handled in one pathway.

• Continuity after return home — CancerFax helps maintain comm

  Continuity after return home — CancerFax helps maintain communication between the Chinese treating team and the patient's local oncologist for follow-up scans, lab work, and any further therapy or BTK inhibitor management.

This comparison is general. Many patients ultimately receive both, in sequence, rather than choosing between them. The treating haematology team makes the final decision based on disease behaviour, prior treatments, fitness, and TP53 status.

Advanced lymphoma care, including approved BTK inhibitor regimens, approved CAR-T therapy, and active mantle cell lymphoma trials, is offered at major academic and specialist centres across China. This includes leading institutions in Beijing, Shanghai, Guangzhou, Tianjin, and other cities, with strong programmes at the Chinese Academy of Medical Sciences and National Cancer Center, Fudan University Shanghai Cancer Center, Renji Hospital, Ruijin Hospital, Peking University Cancer Hospital, Sun Yat-sen University Cancer Center, and several dedicated haematology and cell therapy units. The same therapy category can have different eligibility rules, product choices, admission timelines, and cost structures from one hospital to another. The right centre for a given case depends on diagnosis details, urgency, planned product, BTK inhibitor history, and trial availability rather than hospital name alone. CancerFax helps match the case with a centre that fits the clinical situation, not the other way around.

Frequently Asked Questions

Answers to common questions from patients and families.

Structured reference data summarizing key information for this topic.